Day One Bio (DAWN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Graphic logo of Day One Bio (DAWN)

The line of targeted therapies for children is entering a stage of commercial growth, ensuring a protected patent cycle. Reviewing the EV/EBITDA multiple for Day One (DAWN) over time on GURU.Markets, we see that the 0.00 metric confirms the current valuation level. This is further supported by the high authority of Day One in treating brain tumors, while the orphan drug status of its products guarantees a monopoly position and stable revenue.

DAWN Day One Biopharmaceuticals, Inc.: Enterprise Value to Operating Income Before Depreciation in the range 11/23/2025 - 05/09/2026

DAWN (dayonebio.com): analytical breakdowns and indicator data

- stock price and consensus target price:
Stock Quotes Day One Bio|DAWN - Fair Value Consensus
- market capitalization indicators:
Market Value Day One Biopharmaceuticals Inc|DAWN - Total Enterprise Value
- book value of equity indicators:
Net Assets per Single Share Day One Biopharmaceuticals|DAWN - Accounting Capitalization|Market Capitalization to Book Value Ratio dayonebio.com|DAWN - Cumulative Company Assets
- debt and liquidity data:
Debt to Equity Day One|DAWN - Long-Term Liabilities to Capital|Short-Term Debt to Equity Day One Biopharmaceuticals|DAWN - Company Debts|Debt to Book Capitalization Ratio Day One Biopharmaceuticals Inc|DAWN - Long-Term Debt|Company Short-Term Debts Day One Biopharmaceuticals|Quick Liquidity Indicator dayonebio.com
- business earnings and investment ratios data:
DAWN - Company Net Income|Future Profit Day One|DAWN - Company Value to Net Income|Projected Price to Earnings Day One|DAWN - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Day One Biopharmaceuticals Inc|DAWN - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Day One Biopharmaceuticals|DAWN - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months dayonebio.com|DAWN - Earnings per share increase in current year|Earnings growth forecast for next year Day One
Summary company analytics:DAWN (Day One Bio)
Original product of Day One Biopharmaceuticals

The EV/EBITDA multiple compares the total enterprise value, including debt, with operating profit, allowing for an assessment of capital management efficiency and debt load. The current value of 0.00 and the fluctuations in the EV/EBITDA level of Day One (DAWN) demonstrate the stability of grant-based financing, which is critical for Day One as it scales distribution and brings its pediatric oncology drug to market.

Competitor analysis

Incyte Corp. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation HCM|NUVB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA monopartx.com|Inhibrx Biosciences, Inc. (INBX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation IMAB|FENC (Fennec Pharmaceuticals Inc) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Heron Therapeutics Inc (HRTX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Nuvectis Pharma, Inc. (NVCT)|CHRS - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Corbus Pharmaceuticals Holdings CRBP|Cardiff Oncology Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|BYSI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA BioAtla, Inc.|LIXT: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Citius Pharmaceuticals, Inc. CTXR|Enterprise Value to EBITDA Ratio CLRB|Company Value to EBITDA BioLineRx Ltd BLRX|Enterprise Value to EBITDA Ratio CANF (Can-Fite BioPharma, Ltd.)|APRE (aprea.com) - Business Value to Operating Income Before Depreciation|Kazia Therapeutics Limited - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio SLXN (Silexion Therapeutics Corp.)|NuCana Corp - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation CMRX (Chimerix Inc.)|CYCC: EV/EBITDA Multiple|Company Value to EBITDA G1 Therapeutics (GTHX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Kronos Bio, Inc.|KTRA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ONCT|EV/EBITDA Multiple Portage Biotech Inc (PRTG)